Identification Name Decitabine Accession Number DB01262 Type Small Molecule Groups Approved, Investigational Description Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Decitabine incorporate it into DNA during replication and RNA during transcription. The incorporation of Decitabine into DNA or RNA inhibits methyltransferase thereby causing demethylation in that sequence. This adversely affects the way that cell regulatory proteins are able to bind to the DNA/RNA substrate.
Structure Synonyms 4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one 5-aza-2'-deoxycytidine 5-Azadeoxycytidine Azadc Decitabine Dezocitidine
External IDs NSC-127716 Product Ingredients Not Available Approved Prescription Products Name Dosage Strength Route Labeller Marketing Start Marketing End Dacogen Injection, powder, lyophilized, for solution 50 mg/20mL Intravenous Eisai Limited 1996-05-03 2018-12-31 US Dacogen Injection, powder, for solution 50 mg Intravenous Janssen Cilag International Nv 2012-09-20 Not applicable EU Dacogen Injection, powder, lyophilized, for solution 50 mg/20mL Intravenous Otsuka Pharmaceutical Co., Ltd. 1996-05-03 Not applicable US Decitabine Kit Sun Pharma Global FZE 2014-01-24 Not applicable US
Approved Generic Prescription Products Name Dosage Strength Route Labeller Marketing Start Marketing End Decitabine Injection, powder, lyophilized, for solution 50 mg/50mL Intravenous Sandoz 2014-08-28 Not applicable US Decitabine Injection, powder, lyophilized, for solution 50 mg/20mL Intravenous Accord Healthcare Limited 2017-03-08 Not applicable US Decitabine Injection, powder, lyophilized, for solution 50 mg/50mL Intravenous Dr Reddy's Laboratories 2013-07-11 Not applicable US Decitabine Injection, powder, lyophilized, for solution 50 mg/50mL Intravenous Dr Reddy's Laboratories 2013-07-11 Not applicable US Decitabine Injection, powder, lyophilized, for solution 50 mg/50mL Intravenous Dr Reddy's Laboratories 2014-12-05 Not applicable US
Approved Over the Counter Products Not Available Unapproved/Other Products Not Available International Brands Not Available Brand mixtures Not Available Categories UNII 776B62CQ27 CAS number 2353-33-5 Weight Average: 228.2053 Chemical Formula C8 H12 N4 O4 InChI Key XAUDJQYHKZQPEU-KVQBGUIXSA-N InChI InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
IUPAC Name 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one
SMILES Pharmacology Indication For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups (scores ≥0.5).
Structured Indications Pharmacodynamics Decitabine is an analogue of the natural nucleoside 2’-deoxycytidine. It functions in the same way as 5-Azacytidine. The antineoplastic activity of this drug is dependent on its intracellular conversion to its 5'-triphosphate metabolite.
Mechanism of action Decitabine is believed to exert its antineoplastic effects following its conversion to decitabine triphosphate, where the drug directly incorporates into DNA and inhibits DNA methyltransferase, the enzyme that is responsible for methylating newly synthesized DNA in mammalian cells. This results in hypomethylation of DNA and cellular differentiation or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine that has been incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine. Decitabine is cell cycle specific and acts peripherally in the S phase of the cell cycle. It does not inhibit the progression of cells from the G1 to S phase.
Target Kind Pharmacological action Actions Organism UniProt ID DNA Nucleotide yes other/unknown
Human not applicable details DNA (cytosine-5)-methyltransferase 1 Protein yes inhibitor
Human P26358 details
Related Articles
Absorption Not Available Volume of distribution Not Available Protein binding Plasma protein binding of decitabine is negligible (<1%).
Metabolism
The exact route of elimination and metabolic fate of decitabine is not known in humans. One of the pathways of elimination of decitabine appears to be deamination by cytidine deaminase found principally in the liver but also in granulocytes, intestinal epithelium and whole blood.
Route of elimination Not Available Half life The terminal phase elimination half-life is 0.51 ± 0.31 hours.
Clearance
125 L/h/m2 [Patients receiving 15 mg/m2 3-hr infusion every 8 hours for 3 days]
210 L/h/m2 [20 mg/m2 1-hr infusion daily for 5 days]
Toxicity There is no known antidote for overdosage with decitabine. Higher doses are associated with increased myelosuppression including prolonged neutropenia and thrombocytopenia.
Affected organisms Pathways Not Available Pharmacogenomic Effects/ADRs Not Available Interactions Drug Interactions Drug Interaction Drug group Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Decitabine. Approved BCG vaccine The therapeutic efficacy of Bcg can be decreased when used in combination with Decitabine. Investigational Bevacizumab Bevacizumab may increase the cardiotoxic activities of Decitabine. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine. Approved Clozapine The risk or severity of adverse effects can be increased when Decitabine is combined with Clozapine. Approved Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Decitabine. Approved, Investigational Deslanoside Deslanoside may decrease the cardiotoxic activities of Decitabine. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Decitabine. Approved Digoxin Digoxin may decrease the cardiotoxic activities of Decitabine. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Decitabine. Approved, Investigational Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Decitabine. Withdrawn Oleandrin Anvirzel may decrease the cardiotoxic activities of Decitabine. Experimental Ouabain Ouabain may decrease the cardiotoxic activities of Decitabine. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Decitabine. Approved, Vet Approved Trastuzumab Trastuzumab may increase the cardiotoxic activities of Decitabine. Approved, Investigational
Food Interactions Not Available References Synthesis Reference Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei, "Synthesis of Decitabine." U.S. Patent US20100087637, issued April 08, 2010.
US20100087637 General References Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9. [PubMed:17925555 ] Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008 Apr;32(4):587-91. Epub 2007 Sep 18. [PubMed:17881052 ] Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10. [PubMed:20072836 ] Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. [PubMed:16015501 ] Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. doi: 10.1002/cncr.23463. [PubMed:18398832 ] Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607. [PubMed:18425818 ] Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. [PubMed:17023173 ] External Links ATC Codes L01BC08 — Decitabine AHFS Codes Not Available PDB Entries Not Available FDA label Download (100 KB) MSDS Not Available Clinical Trials Clinical Trials Phase Status Purpose Conditions Count 0 Recruiting Treatment Aggressive B-cell Lymphoma / Indolent B-cell Lymphoma / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas 1 0 Recruiting Treatment Pancreatic Adenocarcinoma Metastatic 1 1 Active Not Recruiting Treatment Acute Myelogenous Leukaemia (AML) / Myelogenous Leukemia / Treatment Naive AML 1 1 Active Not Recruiting Treatment Acute Myeloid Leukaemias (AML) 2 1 Active Not Recruiting Treatment Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome 1 1 Active Not Recruiting Treatment Acute Myeloid Leukaemias (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Active Not Recruiting Treatment Acute Myeloid Leukaemias (AML) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Active Not Recruiting Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Active Not Recruiting Treatment Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Active Not Recruiting Treatment Hematopoetic Myelodysplasia / Leukemia, Lymphoblastic, Acute / Leukemia, Myeloid Acute 1 1 Completed Treatment Acute Myeloid Leukaemias (AML) / AML 1 1 Completed Treatment Acute Lymphocytic Leukemia (ALL) 1 1 Completed Treatment Acute Myeloid Leukaemias (AML) 3 1 Completed Treatment Acute Myeloid Leukaemias (AML) / Alkylating Agent-Related Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Refractory Anemia With Excess Blasts in Transformation 1 1 Completed Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Chronic Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Philadelphia Chromosome Negative Chronic Myelogenous Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia 1 1 Completed Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Completed Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Secondary Acute Myeloid Leukemia / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Completed Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Completed Treatment Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Completed Treatment Advanced Esophageal Cancers / Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura / Non-Small-Cell Lung Carcinoma (NSCLC) / Pleural Mesotheliomas / Primary Small Cell Lung Cancers 1 1 Completed Treatment Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific 1 1 Completed Treatment Chronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms 1 1 Completed Treatment Colorectal Cancers 1 1 Completed Treatment Esophageal Cancers / Lung Cancers / Mesothelioma, Malignant / Metastatic Cancers 1 1 Completed Treatment Leukemia, Myelocytic, Acute Myelodysplastic Syndromes / Myelodysplastic Syndromes 1 1 Completed Treatment Leukemia, Myeloid, Acute 1 1 Completed Treatment Leukemia, Myeloid, Acute / Myelodysplastic Syndromes 1 1 Completed Treatment Leukemias 1 1 Completed Treatment Male Breast Cancer / Recurrent Bladder Cancer / Recurrent Breast Cancer / Recurrent Melanoma / Stage III Melanoma / Stage IV Bladder Cancer / Stage IV Breast Cancer / Stage IV Melanoma / Unspecified Adult Solid Tumor, Protocol Specific 1 1 Completed Treatment Melanoma 1 1 Completed Treatment Myelodysplastic Syndrome 2 1 Completed Treatment Myelodysplastic Syndromes 1 1 Completed Treatment Myelodysplastic Syndromes and Leukemia, Myeloid, Acute 1 1 Completed Treatment Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma 1 1 Completed Treatment Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer 1 1 Completed Treatment Recurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific 1 1 Completed Treatment Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 1 Not Yet Recruiting Treatment Acute Myeloid Leukaemias (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / TP53 wt Allele / Untreated Adult Acute Myeloid Leukemia 1 1 Not Yet Recruiting Treatment Agnogenic Myeloid Metaplasia / Atypical Chronic Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndromes / Myeloproliferative Neoplasms 1 1 Not Yet Recruiting Treatment Fallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma 1 1 Recruiting Treatment Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Hematopoietic/Lymphoid Cancer 1 1 Recruiting Treatment Acute Myeloid Leukaemias (AML) 1 1 Recruiting Treatment Acute Myeloid Leukaemias (AML) / Chimerism / Hematopoietic Cell Transplantation Recipient / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / Previously Treated Myelodysplastic Syndromes / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Recruiting Treatment Bone Marrow Diseases / Hematologic Diseases / Leukemia, Myeloid, Acute / Leukemias / Myelodysplastic Syndrome / Myelodysplastic Syndromes / Myeloid Leukemias 1 1 Recruiting Treatment De Novo Myelodysplastic Syndrome / Mixed Phenotype Acute Leukemia (MPAL) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Recruiting Treatment Pancreatic Ductal Adenocarcinoma / Sarcomas 1 1 Recruiting Treatment Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Suspended Treatment Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 1 Terminated Treatment Acute Myeloid Leukaemias (AML) / Untreated Adult Acute Myeloid Leukemia 1 1 Terminated Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / De Novo Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia 1 1 Terminated Treatment Cancers 1 1 Terminated Treatment Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Promyelocytic Leukemia (M3) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia 1 1 Terminated Treatment Hematopoietic/Lymphoid Cancer / Unspecified Adult Solid Tumor, Protocol Specific 1 1 Terminated Treatment Leukemias 1 1 Terminated Treatment Myelodysplastic Syndrome 1 1 Terminated Treatment Unspecified Adult Solid Tumor, Protocol Specific 1 1 Withdrawn Treatment Melanoma / Neoplasms Metastasis / Neoplasms, Germ Cell and Embryonal / Sarcomas 1 1, 2 Active Not Recruiting Treatment Leukemias 1 1, 2 Active Not Recruiting Treatment Myelodysplastic Syndromes 1 1, 2 Active Not Recruiting Treatment Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia 1 1, 2 Completed Treatment AML / Smith-Magenis Syndrome 1 1, 2 Completed Treatment Cancer, Ovarian 1 1, 2 Completed Treatment Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Thrombocytopenias 1 1, 2 Completed Treatment Leukemia, Myeloid, Acute / Myelodysplastic Syndromes 1 1, 2 Completed Treatment Leukemias 1 1, 2 Completed Treatment Leukemias / Myelodysplastic Syndromes 2 1, 2 Completed Treatment Malignant Melanoma 1 1, 2 Completed Treatment Metastatic Melanoma 1 1, 2 Completed Treatment Myelodysplastic Syndromes 1 1, 2 Not Yet Recruiting Treatment Acute Myeloid Leukaemias (AML) 1 1, 2 Not Yet Recruiting Treatment Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes 1 1, 2 Not Yet Recruiting Treatment Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) 1 1, 2 Not Yet Recruiting Treatment Myelodysplastic Syndromes 1 1, 2 Recruiting Treatment AML 1 1, 2 Recruiting Treatment Acute Myelogenous Leukaemia (AML) 1 1, 2 Recruiting Treatment Acute Myeloid Leukaemias (AML) 1 1, 2 Recruiting Treatment Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes 1 1, 2 Recruiting Treatment Acute Myeloid Leukemia, in Relapse / Recurrent Adult Acute Myeloid Leukemia 1 1, 2 Recruiting Treatment BRAF-mutated Metastatic Melanoma / Melanoma / Metastatic Melanoma / V600EBRAF-mutated Metastatic Melanoma 1 1, 2 Recruiting Treatment Cancers 1 1, 2 Recruiting Treatment Colorectal Cancers / Liver Metastasis 1 1, 2 Recruiting Treatment Leukemias 2 1, 2 Recruiting Treatment Leukemias / Myeloproliferative Diseases 1 1, 2 Recruiting Treatment Lymphoma, B Cell / Tumors, Solid 1 1, 2 Recruiting Treatment Lymphoma, Hodgkins 1 1, 2 Recruiting Treatment Lymphoma, Large B-Cell, Diffuse (DLBCL) 1 1, 2 Recruiting Treatment Malignancies Multiple 1 1, 2 Recruiting Treatment Myelodysplastic Syndrome / Smith-Magenis Syndrome 1 1, 2 Recruiting Treatment Myeloproliferative Neoplasms 1 1, 2 Recruiting Treatment Recurrent Adult Acute Myeloid Leukemia 1 1, 2 Recruiting Treatment Relapsed Acute Myeloid Leukemia 1 1, 2 Terminated Treatment Acute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia 1 1, 2 Terminated Treatment Cancer, Breast / Neoplasms, Breast / Tumors, Breast 1 1, 2 Terminated Treatment Gliomas / Medulloblastomas / Neuroectodermal Tumors, Primitive 1 1, 2 Unknown Status Treatment Acute Myeloid Leukaemias (AML) 1 2 Active Not Recruiting Prevention Acute Myeloid Leukaemias (AML) 1 2 Active Not Recruiting Treatment Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / AML (Adult) With 11q23 (MLL) Abnormalities / AML (Adult) With Del(5q) / AML (Adult) With Inv(16)(p13;q22) / AML (Adult) With t(16;16)(p13;q22) / AML (Adult) With t(8;21)(q22;q22) / Secondary Acute Myeloid Leukemia / Secondary AML (Adult) / Untreated Adult Acute Myeloid Leukemia / Untreated AML (Adult) 1 2 Active Not Recruiting Treatment Acute Myeloid Leukaemias (AML) 3 2 Active Not Recruiting Treatment Acute Myeloid Leukaemias (AML) / Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 2 Active Not Recruiting Treatment Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 2 Active Not Recruiting Treatment Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia 1 2 Active Not Recruiting Treatment Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Untreated Adult Acute Myeloid Leukemia 1 2 Active Not Recruiting Treatment Chronic Myelomonocytic Leukemia 1 2 Active Not Recruiting Treatment Leukemias 4 2 Active Not Recruiting Treatment Myelodysplastic Syndrome 1 2 Active Not Recruiting Treatment Primary Myelofibrosis / Secondary Myelofibrosis 1 2 Completed Not Available Chronic Myelomonocytic Leukemia 1 2 Completed Basic Science Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Myeloproliferative/Myelodysplastic Neoplasm 1 2 Completed Supportive Care Myelodysplastic Syndromes / Smith-Magenis Syndrome / Thrombocytopenias 1 2 Completed Treatment Accelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Relapsing Chronic Myelogenous Leukemia 1 2 Completed Treatment Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome 4 2 Completed Treatment Acute Myeloid Leukaemias (AML) 3 2 Completed Treatment Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome 1 2 Completed Treatment Acute Myeloid Leukemia With Multilineage Dysplasia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia 1 2 Completed Treatment Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts 1 2 Completed Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 2 Completed Treatment Chronic Myelogenous Leukemia (CML) 3 2 Completed Treatment Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1 2 Completed Treatment Leukemias / Myelodysplastic Syndromes 1 2 Completed Treatment Myelodysplastic Syndrome 5 2 Completed Treatment Myelodysplastic Syndrome / Smith-Magenis Syndrome 1 2 Completed Treatment Neutropenias / Sickle Cell Disorders 1 2 Completed Treatment Pediatric Acute Myelogenous Leukemia (AML) 1 2 Completed Treatment Recurrent Thyroid Cancer / Stage IVA Follicular Thyroid Cancer / Stage IVA Papillary Thyroid Cancer / Stage IVB Follicular Thyroid Cancer / Stage IVB Papillary Thyroid Cancer / Stage IVC Follicular Thyroid Cancer / Stage IVC Papillary Thyroid Cancer 1 2 Completed Treatment Thalassaemic disorders 1 2 Recruiting Treatment Acute Myeloid Leukaemias (AML) 2 2 Recruiting Treatment Acute Myeloid Leukaemias (AML) / Acute Myeloid Leukemia, Relapsed, Adult 1 2 Recruiting Treatment Acute Myeloid Leukaemias (AML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1 2 Recruiting Treatment Acute Myeloid Leukaemias (AML) / Complex Karyotype 1 2 Recruiting Treatment Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes 1 2 Recruiting Treatment Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Adult Acute Myeloid Leukemia 1 2 Recruiting Treatment Acute Myeloid Leukemia With FLT3/ITD Mutation / Acute Myeloid Leukemia With Gene Mutations / FLT3 Tyrosine Kinase Domain Point Mutation / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 2 Recruiting Treatment Adult Acute Myeloid Leukemia / Adult Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia 1 2 Recruiting Treatment Advanced Non-Small Cell Lung Cancer / Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Recruiting Treatment Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Secondary Myelodysplastic Syndromes 1 2 Recruiting Treatment Immune Thrombocytopenia 1 2 Recruiting Treatment Leukemia, Myeloid, Acute 1 2 Recruiting Treatment Leukemia, Myeloid, Acute / Myelodysplastic Syndromes 1 2 Recruiting Treatment Leukemias 4 2 Recruiting Treatment Myelodysplastic Syndromes 1 2 Terminated Treatment Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 2 Terminated Treatment Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer 1 2 Terminated Treatment Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1 2 Terminated Treatment Chronic Myeloproliferative Disorders / Secondary Myelofibrosis 1 2 Terminated Treatment Leukemias 1 2 Terminated Treatment Leukemias / Malignant Lymphomas 1 2 Terminated Treatment Myelodysplastic Syndrome 1 2 Terminated Treatment Renal Cell Adenocarcinoma 1 2 Unknown Status Treatment Acute Myeloid Leukaemias (AML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1 2 Withdrawn Treatment Melanoma 1 2, 3 Completed Treatment Acute Myelogenous Leukaemia (AML) 1 2, 3 Not Yet Recruiting Treatment Acute Myeloid Leukaemias (AML) / Adult Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-2 / Untreated Adult Acute Myeloid Leukemia 1 2, 3 Recruiting Treatment Allogeneic peripheral haematopoietic stem cell transplant / Conditioning / Myelodysplastic Syndrome 1 2, 3 Recruiting Treatment Allogeneic peripheral haematopoietic stem cell transplant / Myelodysplastic Syndrome 1 2, 3 Recruiting Treatment FIGO Stages II to IV / Primary Malignant Neoplasm of Ovary 1 2, 3 Unknown Status Treatment Acute Myelocytic Leukemia / Myelodysplastic Syndromes 1 2, 3 Unknown Status Treatment Myelodysplastic Syndromes 1 3 Active Not Recruiting Treatment Leukemia, Myeloid, Acute 1 3 Completed Treatment Acute Myeloid Leukaemias (AML) 1 3 Completed Treatment Myelodysplastic Syndrome 1 3 Enrolling by Invitation Treatment Acute Myeloid Leukemia, Adult 1 3 No Longer Available Not Available Myelodysplastic Syndromes 1 3 Not Yet Recruiting Treatment Hematologic Diseases / Thrombocytopenias 1 3 Not Yet Recruiting Treatment Immune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic 1 3 Recruiting Treatment Acute Myeloid Leukaemias (AML) 2 3 Recruiting Treatment Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia 1 3 Recruiting Treatment Leukemias 1 3 Recruiting Treatment Smith-Magenis Syndrome 1 3 Unknown Status Treatment Acute Myeloid Leukaemias (AML) 1 3 Unknown Status Treatment Drug Safety / Effect of Drugs / Untreated Adult Acute Myeloid Leukemia 1 3 Unknown Status Treatment Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms 1 4 Active Not Recruiting Prevention Acute Myeloid Leukaemias (AML) 1 4 Completed Not Available Myelodysplastic Syndrome 1 4 Completed Not Available Myelodysplastic Syndromes 1 4 Terminated Treatment Myelodysplastic Syndromes 1 4 Unknown Status Treatment Higher-risk Myelodysplastic Syndrome / Relapsed /Refractory Acute Myeloid Leukemia 1 4 Unknown Status Treatment Myelodysplastic Syndrome 1 Not Available Active Not Recruiting Treatment Chronic Myelomonocytic Leukemia-2 / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Untreated Adult Acute Myeloid Leukemia 1 Not Available Completed Not Available Acute iron intoxication / Beta-Thalassemia / Bone destruction / Hematologic Diseases / Pulmonary Hypertension (PH) / Thalassaemic disorders / Thalassemia Major (TM) 1 Not Available Not Yet Recruiting Not Available Acute Myeloid Leukaemias (AML) / Elderly / Intensive Chemotherapy Unfit 1 Not Available Not Yet Recruiting Treatment Malignant Neoplasm of Pancreas 1 Not Available Recruiting Not Available Malignant Neoplasm of Colon 1 Not Available Recruiting Treatment Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia 1 Not Available Recruiting Treatment Myelodysplastic Syndromes (MDS) 1
Pharmacoeconomics Manufacturers Not Available Packagers Dosage forms Form Route Strength Injection, powder, for solution Intravenous 50 mg Injection, powder, lyophilized, for solution Intravenous 50 mg/20mL Injection, powder, lyophilized, for solution Intravenous 50 mg/50mL Kit
Prices Unit description Cost Unit Dacogen 50 mg vial 1706.4USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents Not Available Properties State Solid Experimental Properties Property Value Source water solubility Sparingly soluble Not Available
Predicted Properties Predicted ADMET features Property Value Probability Human Intestinal Absorption + 0.9862 Blood Brain Barrier + 0.8787 Caco-2 permeable - 0.8362 P-glycoprotein substrate Non-substrate 0.7192 P-glycoprotein inhibitor I Non-inhibitor 0.9216 P-glycoprotein inhibitor II Non-inhibitor 0.953 Renal organic cation transporter Non-inhibitor 0.8791 CYP450 2C9 substrate Non-substrate 0.8359 CYP450 2D6 substrate Non-substrate 0.8511 CYP450 3A4 substrate Non-substrate 0.5356 CYP450 1A2 substrate Non-inhibitor 0.9276 CYP450 2C9 inhibitor Non-inhibitor 0.9265 CYP450 2D6 inhibitor Non-inhibitor 0.9446 CYP450 2C19 inhibitor Non-inhibitor 0.9379 CYP450 3A4 inhibitor Non-inhibitor 0.9635 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9629 Ames test Non AMES toxic 0.588 Carcinogenicity Non-carcinogens 0.8109 Biodegradation Not ready biodegradable 0.8957 Rat acute toxicity 1.9436 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9654 hERG inhibition (predictor II) Non-inhibitor 0.8972
ADMET data is predicted using
admetSAR , a free tool for evaluating chemical ADMET properties. (
23092397 )
Spectra Mass Spec (NIST) Not Available Spectra Taxonomy Description This compound belongs to the class of organic compounds known as triazinones. These are compounds containing a triazine ring which bears a ketone group a carbon atom. Kingdom Organic compounds Super Class Organoheterocyclic compounds Class Triazines Sub Class Triazinones Direct Parent Triazinones Alternative Parents Aminotriazines / 1,3,5-triazines / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds / Primary amines / Primary alcohols / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives show 2 moreSubstituents Amino-1,3,5-triazine / Aminotriazine / Triazinone / 1,3,5-triazine / Tetrahydrofuran / Heteroaromatic compound / Secondary alcohol / Oxacycle / Azacycle / Organic oxide / Organopnictogen compound / Alcohol / Primary amine / Primary alcohol / Organooxygen compound / Organonitrogen compound / Organic oxygen compound / Organic nitrogen compound / Amine / Hydrocarbon derivative / Aromatic heteromonocyclic compound show 11 moreMolecular Framework Aromatic heteromonocyclic compounds External Descriptors 2'-deoxyribonucleoside (CHEBI:50131 ) 
